As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

When Io­n­is and As­traZeneca un­veiled the first round of mid-stage da­ta for their an­ti­sense PC­SK9 drug, Mene Pan­ga­los, As­traZeneca’s EVP of bio­phar­ma­ceu­ti­cals R&D, un­der­scored the drug’s “po­ten­tial best-in-class ef­fi­ca­cy pro­file.”

But now that the sec­ond batch is in, it ap­pears AZD8233 isn’t hit­ting the mark af­ter all.

Io­n­is an­nounced Fri­day morn­ing that al­though the can­di­date, al­so dubbed ION449, met the pri­ma­ry end­point in the Phase IIb SOLANO tri­al, its part­ners at As­traZeneca have de­cid­ed not to move it in­to Phase III stud­ies be­cause the “re­sults did not achieve pre-spec­i­fied ef­fi­ca­cy cri­te­ria.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER